ATE445163T1 - Verfahren zur beurteilung der gefahr und veranlagung, eine mit dem vorliegen von anti-epcr-antikörpern verbundene symptomatik zu entwickeln - Google Patents
Verfahren zur beurteilung der gefahr und veranlagung, eine mit dem vorliegen von anti-epcr-antikörpern verbundene symptomatik zu entwickelnInfo
- Publication number
- ATE445163T1 ATE445163T1 AT05701698T AT05701698T ATE445163T1 AT E445163 T1 ATE445163 T1 AT E445163T1 AT 05701698 T AT05701698 T AT 05701698T AT 05701698 T AT05701698 T AT 05701698T AT E445163 T1 ATE445163 T1 AT E445163T1
- Authority
- AT
- Austria
- Prior art keywords
- presidency
- assessing
- risk
- symptoms associated
- epcr
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 101800004937 Protein C Proteins 0.000 abstract 2
- 102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 abstract 2
- 101800001700 Saposin-D Proteins 0.000 abstract 2
- 229960000856 protein c Drugs 0.000 abstract 2
- 102000009839 Endothelial Protein C Receptor Human genes 0.000 abstract 1
- 108010009900 Endothelial Protein C Receptor Proteins 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 108091007231 endothelial receptors Proteins 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000011002 quantification Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200400269A ES2239532B1 (es) | 2004-02-06 | 2004-02-06 | Metodo para evaluar el riesgo y la predisposicion a desarrollar una patologia relacionada con la presencia de autoanticuerpos frente a epcr. |
| PCT/ES2005/000046 WO2005076000A1 (es) | 2004-02-06 | 2005-02-03 | Método para evaluar el riesgo y la predisposición a desarrollar una patologia relacionada con la presencia de autoanticuerpos frente a epcr |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE445163T1 true ATE445163T1 (de) | 2009-10-15 |
Family
ID=34833893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05701698T ATE445163T1 (de) | 2004-02-06 | 2005-02-03 | Verfahren zur beurteilung der gefahr und veranlagung, eine mit dem vorliegen von anti-epcr-antikörpern verbundene symptomatik zu entwickeln |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1722229B8 (de) |
| JP (1) | JP2007520713A (de) |
| CN (1) | CN1954216A (de) |
| AT (1) | ATE445163T1 (de) |
| AU (1) | AU2005210776A1 (de) |
| BR (1) | BRPI0506635A (de) |
| CA (1) | CA2555783A1 (de) |
| DE (1) | DE602005017016D1 (de) |
| ES (1) | ES2239532B1 (de) |
| MX (1) | MXPA06008799A (de) |
| RU (1) | RU2375716C2 (de) |
| WO (1) | WO2005076000A1 (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090286256A1 (en) * | 2008-05-19 | 2009-11-19 | Abbott Laboratories | Isolated human autoantibodies to natriuretic peptides and methods and kits for detecting human autoantibodies to natriuretic peptides |
| WO2010128506A2 (en) | 2009-05-05 | 2010-11-11 | Yeda Research & Development Co. Ltd. | Means and methods for recognizing the development of cardiovascular disease in an individual |
| WO2011099012A1 (en) * | 2010-02-12 | 2011-08-18 | Yeda Research And Development Co. Ltd. | Diagnosis of systemic lupus erythematosus (sle) |
| NZ609363A (en) * | 2010-10-18 | 2015-04-24 | Nestec Sa | Methods for determining anti-drug antibody isotypes |
| EA018848B1 (ru) * | 2010-10-20 | 2013-11-29 | Вадим Юльевич ШАНИН | Иммунологически активное вещество, способ его получения, биозонд на его основе и способ диагностики состояния здоровья с применением биозонда, фармацевтическая композиция и способ лечения с использованием фармацевтической композиции |
| EP2927690B1 (de) * | 2011-02-02 | 2022-10-26 | Academisch Ziekenhuis Leiden h.o.d.n. LUMC | Anticarbamylierte Protein-Antikörper und Arthritisgefahr |
| RU2586412C2 (ru) * | 2012-06-09 | 2016-06-10 | Общество с ограниченной ответственностью научно-технический центр "БиоКлиникум" (ООО НТЦ "БиоКлиникум") | Способ оценки риска возникновения патологии беременности |
| RU2517051C1 (ru) * | 2013-01-09 | 2014-05-27 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кемеровский государственный университет" (КемГУ) | Способ определения вероятности возникновения врожденных пороков развития плода у беременных женщин |
| CN104655860A (zh) * | 2013-11-21 | 2015-05-27 | 苏州中赢医疗科技有限公司 | 一种类风湿性关节炎的诊断标志 |
| WO2015101988A1 (en) | 2013-12-31 | 2015-07-09 | Yeda Research And Development Co. Ltd. | Diagnosis of systemic lupus erythematosus using oligonucleotides antigens |
| US11047855B2 (en) | 2015-03-01 | 2021-06-29 | Immunarray Ltd. | Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens |
| JP7812985B2 (ja) * | 2019-12-30 | 2026-02-12 | ウニヴェルシテーツメディツィン・デア・ヨハネス・グーテンベルク－ウニヴェルシテート・マインツ | 病原性抗リン脂質抗体の検出法及び阻害剤の同定法 |
| CN117586418B (zh) * | 2023-11-08 | 2025-07-15 | 东南大学 | 一种丝氨酸蛋白酶抑制剂及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5472883A (en) * | 1992-02-05 | 1995-12-05 | Yamasa Corporation | Solid phase reagent and assay method for measuring antibodies specific to antiphospholipid syndrome |
| US5804392A (en) * | 1997-06-27 | 1998-09-08 | Oklahoma Medical Research Foundation | Diagnostic assays using soluble endothelial cell protein C/activated protein C receptor |
| US6261820B1 (en) * | 1999-10-01 | 2001-07-17 | Amgen Inc. | Fibronolytically active polypeptide |
-
2004
- 2004-02-06 ES ES200400269A patent/ES2239532B1/es not_active Expired - Fee Related
-
2005
- 2005-02-03 JP JP2006551864A patent/JP2007520713A/ja not_active Withdrawn
- 2005-02-03 CA CA002555783A patent/CA2555783A1/en not_active Abandoned
- 2005-02-03 DE DE602005017016T patent/DE602005017016D1/de not_active Expired - Fee Related
- 2005-02-03 BR BRPI0506635-2A patent/BRPI0506635A/pt not_active IP Right Cessation
- 2005-02-03 CN CNA2005800068535A patent/CN1954216A/zh active Pending
- 2005-02-03 AT AT05701698T patent/ATE445163T1/de not_active IP Right Cessation
- 2005-02-03 WO PCT/ES2005/000046 patent/WO2005076000A1/es not_active Ceased
- 2005-02-03 EP EP05701698A patent/EP1722229B8/de not_active Expired - Lifetime
- 2005-02-03 AU AU2005210776A patent/AU2005210776A1/en not_active Abandoned
- 2005-02-03 MX MXPA06008799A patent/MXPA06008799A/es unknown
- 2005-02-03 RU RU2006132064/15A patent/RU2375716C2/ru active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2375716C2 (ru) | 2009-12-10 |
| MXPA06008799A (es) | 2007-04-17 |
| JP2007520713A (ja) | 2007-07-26 |
| WO2005076000A8 (es) | 2005-10-27 |
| EP1722229B8 (de) | 2009-11-25 |
| ES2239532A1 (es) | 2005-09-16 |
| CN1954216A (zh) | 2007-04-25 |
| BRPI0506635A (pt) | 2007-05-08 |
| EP1722229B1 (de) | 2009-10-07 |
| ES2239532B1 (es) | 2006-11-01 |
| CA2555783A1 (en) | 2005-08-18 |
| AU2005210776A1 (en) | 2005-08-18 |
| EP1722229A1 (de) | 2006-11-15 |
| DE602005017016D1 (de) | 2009-11-19 |
| WO2005076000A1 (es) | 2005-08-18 |
| RU2006132064A (ru) | 2008-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE445163T1 (de) | Verfahren zur beurteilung der gefahr und veranlagung, eine mit dem vorliegen von anti-epcr-antikörpern verbundene symptomatik zu entwickeln | |
| ATE556030T1 (de) | Ultrasensitiver nachweis von analyten | |
| WO2006126008A3 (en) | Improved immunoassay methods | |
| ATE452343T1 (de) | Verbesserte vitamin-d-messung | |
| DK0820522T3 (da) | Assays og indretninger til detektering af ekstrahepatisk galdeatresi | |
| ATE425266T1 (de) | Aptamer-nanopartikelkonjugate und verwendungsverfahren zur detektion von zielanalyten | |
| WO2006014351A3 (en) | Exploring fluorophore microenvironments | |
| WO2007025044A3 (en) | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators | |
| ATE514950T1 (de) | Verfahren zur untersuchung von sepsis bei menschen | |
| ATE408829T1 (de) | Verfahren und assaykits zum nachweis mononuklearer zellphänotypen | |
| DE60021369D1 (de) | Verfahren zur abschätzung eines magengeschwür-risikos | |
| SG157244A1 (en) | Point of care test for the detection of exposure or immunity to dengue virus | |
| ATE479101T1 (de) | Verfahren zur quantifizierung von denaturiertem lipoprotein | |
| ATE405832T1 (de) | Verfahren zur erhöhung des dynamischen messbereichs von auf spezifischen bindereaktionen basierenden, insbesondere immunologischen testelementen | |
| ATE529533T1 (de) | Verfahren zum nachweis von analyten in einer probe | |
| DE602005014386D1 (de) | Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome | |
| Wang et al. | Developing a novel and simple biosensor for Cystatin C as a fascinating marker of glomerular filtration rate with DNase I-aided recycling amplification strategy | |
| DE602005009925D1 (de) | Verfahren zur beurteilung rheumatoider arthritis durch messen von anti-ccp und serumamyloid a | |
| ATE528651T1 (de) | Diagnoseverfahren für pulmonale arterielle hypertonie | |
| CY1113013T1 (el) | Βελτιωμενες μεθοδοι ανοσολογικων δοκιμασιων | |
| ATE520985T1 (de) | Verfahren zur bestimmung von antigen und antikörper gegen das antigen | |
| DE502007001585D1 (de) | Test zum nachweis von pathologischen prionen | |
| ATE391914T1 (de) | Assay | |
| ATE247831T1 (de) | Verfahren zum nachweis von autoimmun-pathologien | |
| SG165194A1 (en) | Point of care test for the detection of exposure to hev immunoglobulin a (iga) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |